Validation of Saiful Anwar Clinical Congestion Score in Comparison with NT-proBNP for Prediction of Short-term Outcome in Acute Heart Failure with Reduced Ejection Fraction by Adrian, Liemena Harold et al.
Validation of Saiful Anwar Clinical Congestion Score in Comparison 
with NT-proBNP for Prediction of Short-term Outcome in Acute 
Heart Failure with Reduced Ejection Fraction
1
Liemena Harold Adrian1*, Mohammad Saifur Rohman1,2, Muhammad Rizki Fadlan1, Cholid Tri Tjahjono2, 
Anna Fuji Rahimah2, Novi Kurnianingsih2
Brawijaya Cardiovascular Research Center, Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia.
Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia.2
A R T I C L E I N F O A B S T R A C T
1. Introduction
https://doi.org/10.21776/ub.hsj.2020.001.04.06
Received 9 November 2020; Received in revised form 30 November 2020; Accepted 15 December 2020
*Corresponding author at: Brawijaya Cardiovascular Research Center, Department of Cardiology and Vascular Medicine, Faculty of Medicine,
Universitas Brawijaya, Malang, Indonesia
E-mail address: liemenaharold@gmail.com (L.H. Adrian).
Available online 25 December 2020
2214-5400/ ©UB Press. All rights reserved.
Heart Science Journal
Contents list available at www.heartscience.ub.ac.id
Heart Sci J 2020; 1(4): 25-30
Journal Homepage : www.heartscience.ub.ac.id
Background: Risk stratification of acute heart failure (AHF) patients during hospital admission utilizing clinical 
scores emerges as an alternative to standard natriuretic peptide measurement. The development of Saiful Anwar 
clinical congestion score (SACS) as a multivariable predictive model for prediction of short-term outcome in AHF 
with reduced ejection fraction (AHF-rEF) requires validation in comparison to NT-proBNP.
Objective : To validate prognostic value of SACS compare with NT-proBNP in AHF-rEF
Method: This single-center, prospective cohort study was held in dr. Saiful Anwar General Hospital during 
January 2019 to June 2020. From total 89 AHF-rEF patients who admitted to emergency department, were 
assigned to SACS prospective questionnaire fulfillment and NT-proBNP measurement during first 12-hours since 
admission. Patients were divided into two groups based on SACS score and NT-proBNP value during admission. 
90-days follow up was performed after index hospitalization with outcome of interest i.e all-cause mortality 
(ACM) and HF-related rehospitalization (HFR).
Discussion : NT-proBNP level >5180 pg/mL at admission was recognized as an independent predictor 
for short-term outcome in AHF; which is similar with the cut-off point expressed in our study [6]. In 
our study, performance of SACS ≥6 has shown fair discriminative ability with sensitivity 71% and 
specificity 78% for prediction of 90-days ACM, almost similar to the result found in standard biomark-
er NT-proBNP ≥5000 pg/mL (sensitivity 71% and specificity 80%). Additive value of NT-proBNP 
significantly increase the discriminative ability of SACS with sensitivity 86% and specificity 81% for 
predict 90-days ACM
Results : ACM and HFR rate in this study were 16.8% and 22.5%, respectively. SACS ≥6 demonstrated higher 
ACM and HFR rate during 90-days follow-up compared to SACS <6 (p=0.000; p=0.000, respectively). 
Performance of SACS ≥6 on admission showed good discriminative power for predicting 90-days ACM and HFR 
(AUC 0.841, p=0.000; AUC 0.788, p=0.000, respectively) compared to NT-proBNP ≥5000pg/mL (AUC 0.812, 
p=0.000; AUC 0.819, p=0.000, respectively). Additive value of NT-proBNP ≥5000pg/mL on top of SACS ≥6 
increases discriminative power for predicting 90-days ACM and HFR after index hospitalization (AUC 0.836, 
p=0.000; AUC 0.90, p=0.000, respectively).
Conclusion: SACS has demonstrated prognostic value compared to NT-proBNP for prediction of 90-days ACM and 
HFR after index hospitalization in AHF-rEF patients
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 Heart failure (HF) is a global pandemic that affected more 
than 37.7 million world population.1 Prevalence of HF in Southeast 
Asia was reported to be 6.7% in Malaysia, 4.5% in Singapore, and 0.3% 
in Indonesia.2 Data from the local registry in dr. Saiful Anwar General 
Hospital Malang in 2016-2017 demonstrated that 64.5% of patients 
hospitalized for acute worsening of HF had left ventricular ejection 
fraction (LVEF) < 40%, with a higher incidence of in-hospital 
mortality. Despite advances in the diagnosis and treatment of HF, the 
mortality  and rehospitalization rates remain unacceptably high global-
ly.A previous local study revealed 30-day all-cause mortality of 12.9% 
and 30-day HF-related rehospitalization of 20,9% in acute heart failure 
patients hospitalized in Malang.3 30-day HF-related rehospitalization 
of 20,9% in acute heart failure patients hospitalized in Malang.3
 Acute heart failure (AHF) refers to the rapid onset or worsen-
ing of signs and/or symptoms of HF, which is a life-threatening 
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 condition requiring urgent evaluation and treatment, typically leading 
to hospital admission.4 Timely and precise risk stratification of HF 
patients is essential in terms of providing personalized care, especially 
in AHF hospitalization. In order to achieve those goals, evaluation of 
risk profile should be performed at two critical turning points i.e: (1) at 
the time of hospital admission; and (2) at the time of discharge. As a 
result, several predictive scores have been developed and validated in  
AHF.5 However, not all of these prognostic models have prognostic 
value either during admission or at the time of discharge, to predict 
future clinical outcomes.
 N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) is 
widely known as a standard biomarker, accepted by many current 
guidelines, for its diagnostic and prognostic value in AHF evaluation. 
ICON study demonstrated that NT-proBNP >5180 pg/mL during 
admission is an independent predictor for 76-day mortality and 
rehospitalization in AHF.6 However, NT-proBNP itself is not widely 
implemented in daily clinical practice. REPORT-HF registry revealed 
that natriuretic peptide measurement for AHF in many countries only 
accounts for <80% of the population, even in some regions such as 
Southeast Asia, its utilization only accounts for <30% of the total 
population.7 In Indonesia, the implementation of the natriuretic 
peptide is difficult contemplating the archipelagic characteristic, which 
relates to robust availability. Thus, clinical scores emerge as an alterna-
tive to consider.
 A number of validated clinical scores such as Lucas score, 
Rohde score, Larissa score, ELAN-HF score, and EVEREST score had 
already been developed to predict clinical outcome in AHF patients in 
Europe.8 However, in the Asian population, particularly in Indonesia, 
the development of new evidence-based clinical scores considering the 
heterogeneity of demographic characteristics (race, age, comorbidities) 
should be taken into account. Saiful Anwar clinical congestion score 
(SACS) is a multivariable predictive model which has been formerly 
calculated using clinical and laboratory data analysis to add prognostic 
value for prediction of short-term clinical outcome in AHF with reduced 
ejection fraction (AHF-rEF) patients who being hospitalized in dr. 
Saiful Anwar General Hospital Malang. This study is aimed to validate 
whether the SACS will accurately predict short-term outcomes in 
AHF-rEF in comparison to NT-proBNP as a standard biomarker.
2. Method
2.1. Study population
 This is a single-center prospective cohort study. We enrolled 
127 patients with AHF-rEF who admitted to emergency department 
during January 2019 to June 2020 in dr. Saiful Anwar General 
Hospital, Malang – Indonesia. The study design and primary results 
have been reported elsewhere in detail. In brief, patients were included 
if they were aged > 40 years and diagnosed with AHF-rEF (LVEF ≤
40%) within 12-hours of their first evaluation by clinicians. Only the 
first hospitalization during the study period was registered and the AHF 
diagnosis was made based on 2016 ESC Guidelines for the Diagnosis 
and Treatment of Acute and Chronic Heart Failure. Exclusion criteria 
were: 1) pregnancy; 2) LVEF >40%; 3) isolated RV failure; 4) acute 
coronary syndrome; 5) aborted cardiac arrest; 6) on mechanical 
ventilation; 7) cardiac tamponade; 8) congenital heart disease; 9) on 
mechanical/bioprosthetic valve; 10) left atrial myxoma; 11) left atrial 
thrombus; 12) pulmonary vein thrombus; 13) on cardiac resynchroni-
zation therapy; 14) patients who discharge without ACE 
inhibitors/ARB and β-blockers; 15) sepsis; 16) pulmonary embolism 
during one month before admission; 17) pulmonary hypertension 
except for LV dysfunction; 18) acute exacerbation of COPD; 19) 
pneumothorax; 20) CKD on routine dialysis; 21) history of stroke, 
clinical signs of a stroke or TIA; 22) malignancy; 23) terminal medical 
conditions; 24) unwillingness to sign research informed consent. We 
collected clinical assessment, laboratory blood test, chest X-ray, electro-
cardiography, and echocardiography. We used SACS as a result of a 
prior derivation study (as shown in Table 1, Supplementary Table A  
and B). In this study, the evaluation of the patients included SACS 
prospective questionnaire fulfillment and NT-proBNP measurement 
during the first 12-hours of admission. Patients were divided into two 
groups based on SACS during admission. All patients were treated 
using standard HF therapy (diuretic, ACE inhibitor / ARB, and β-block-
er).  During 90-days follow up after discharge, 38 patients were further 
excluded (29 patients demonstrated poor adherence to standard 
medical treatment and 10 patients were lost to follow-up). The study 
complied with the 1975 Declaration of Helsinki and an Institutional 
Review Board or Local Ethical Committee approval was obtained in 
each participating subject.
2.2. Outcomes
 The outcome of interest was defined as all-cause mortality 
(ACM) and HF-related rehospitalization (HFR) within 90-days after the 
index hospitalization. The first event of readmission or death after 
discharge and in-hospital mortality were regarded as the outcome date.
2.5. Statistical analysis
 
Categorical variables are expressed as numbers and percentages. 
Continuous variables are shown as mean and standard deviation. The 
comparison among groups and baseline characteristics were analyzed 
using Chi-squared test and independent T-test. Study variables were 
transformed for further analysis, if necessary. The predictive value of 
SACS was tested using univariate and multivariate logistic regression 
from a prior derivation study. The cut-off point of SACS (≥6) and 
NT-proBNP (≥5000 pg/mL) for 90-days all-cause mortality (ACM) and 
HF-related rehospitalization (HFR) was determined using the ROC 
curve based on the previous derivation set. Analysis of the discriminato-
ry ability of both SACS and NT-proBNP was performed using the ROC 
curve to determine sensitivity and specificity. Kaplan-Meier curves were 
used for survival analysis and hazard ratio measurement for both 
outcomes, and log-rank tests were performed to assess differences in 
survival curves. The Hosmer-Lemeshow test was used to estimate the 
model calibration. Complete case analysis was employed for missing 
data. All statistical analyses were performed with SPSS software 
Version 22. A two-sided p-value <0.05 was considered statistically 
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Table 1. Final score sheet of Saiful Anwar clinical congestion score 





No breathlessness during supine position 0 
Requires more than 1 pillow to avoid 






Never awakened with severe breathlessness 
during sleep 
0 
Often awakened with severe breathlessness 




No rales 0 
Bibasilar rales 1 
Rales at ≤ 50% bilateral of the lung 2 
Shock (at 
admission) 
SBP > 90 mmHg with no sign of peripheral 
hypoperfusion 
0 





Serum sodium level > 120 mmol/L 0 





Serum creatinine level < 1,6 mg/dL 0 
Serum creatinine level > 1,6 mg/dL 1 
Tachycardia (at 
admission) 
Heart rate  < 110 bpm 0 
Heart rate > 110 bpm 1 
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Table 2. Baseline characteristics of the study population based on 
SACS stratification at admission






Age (year) (mean ± SD) 59 ± 10 59 ± 11 0,21 
Sex Female (n, %) 10 (43,3%) 28 (43%) 0,65 
Male (n, %) 13 (56,7%) 38 (57%) 
Comorbidities 
Hypertension (n, %) 12 (52,2%) 34 (51,5%) 0,36 
Diabetes mellitus (n, %) 12 (52,2%) 35 (53%)  0,37 
Cigarette smoking (n, %) 12 (52,2%) 35 (53%) 0,37 
Atrial fibrillation (n, %) 4 (17,4%) 11 (16,8%) 0,64 
Sedentary lifestyle (n, %) 13 (56,6%) 37 (56,1%) 0,38 
History of MI (n, %) 9 (39,1%) 26 (39,4%) 0,79 
History of prior PCI (n, %) 4 (17,4%) 12 (18,1%) 0,36 
History of heart failure (n, %) 13 (56,5%) 37 (56,1%) 0,46 
History of stroke / TIA (n, %) 1 (4,3%) 3 (4,5%) 0,77 
History of CKD (n, %) 1 (4,3%) 3 (4,5%) 0,77 
History of COPD (n, %) 1 (4,3%) 3 (4,5%) 0,77 
History of PAD (n, %) 1 (4,3%) 3 (4,5%) 0,77 
History of alcohol abuse (n, %) 1 (4,3%) 3 (4,5%) 0,77 
Prior history of HF hospitalization (n, %) 13 (56,5%) 37 (56,1%) 0,46 
History of anti-hypertensive medication (n,%) 11 (47,8%) 31 (47%) 0,38 
Clinical Assessment 
Dyspnea on exertion (n, %) 22 (95,6%) 63 (95,4%) 0,74 
Paroxysmal nocturnal dyspnea (n, %) 23 (100%) 60 (91%) 0,01 
Orthopnea (n, %) 23 (100%) 61 (92,4%) 0,02 
Palpitation (n, %) 23 (100%) 61 (92,4%) 0,02 
Fatigue (n, %) 22 (95,6%) 63 (95,4%) 0,74 
Lower extremity edema (n, %) 21 (91,3%) 60 (91%) 0,54 
Diaphoresis (n, %) 8 (34,8%) 23 (34,9%) 0,82 
Increased body weight (n, %) 12 (52,2%) 34 (51,5%) 0,36 
NYHA 
Class I (n, %) 0 0 - 
Class II (n, %) 0 0 - 
Class III (n, %) 8 (34,3%) 23 (34,8%) 0,37 
Class IV (n, %) 15 (65,7%) 43 (65,2%) 0,28 
Forrester 
Dry Warm (n, %) 0 0 - 
Dry Cold (n, %) 0 0 - 
Wet Warm (n, %) 18 (78,2%) 56 (84,3%) 0,06 
Wet Cold (n, %) 5 (21,8%) 10 (15,7%) 0,03 
SBP < 90 mmHg (n, %) 6 (26,1%) 10 (15,7%) <0,001 
SBP > 140 mmHg (n, %) 10 (43,3%) 28 (43%) 0,65 
HR > 100 bpm (n, %) 10 (43,3%) 21 (31,8%) <0,001 
Peripheral hypoperfusion (n, %) 6 (26,1%) 10 (15,7%) <0,001 
JVP > 9 mmHg (n, %) 14 (60,8%) 40 (60,7%) 0,86 
Murmur (n, %) 8 (34,3%) 23 (34,8%) 0,37 
S3/S4 Gallop (n, %) 3 (13,3%) 9 (13,6%) 0,64 
Rales (n, %) 23 (100%) 62 (94%) 0,005 
Wheezing (n, %) 1 (4,3%) 3 (4,5%) 0,77 
Pleural effusion (n, %) 5 (21,7%) 14 (21,2%) 0,36 
Hepatomegaly (n, %) 12 (52,2%) 35 (53%)  0,37 
Hepatojugular reflux (n, %) 12 (52,2%) 35 (53%)  0,37 
Ascites (n, %) 3 (13,3%) 9 (13,6%) 0,64 
 
Haemoglobin (g/dL) (mean ± SD) 14 ± 8 14 ± 7 0,12 
Serum creatinine (mg/dL) (mean ± SD) 1,6 ± 1,0 1,5 ± 0,7 0,04 
AST (U/L) (mean ± SD) 44 ± 28 45 ± 32 0,34 
ALT (U/L) (mean ± SD) 39 ± 19 39 ± 21 0,37 
Total cholesterol (mg/dL) (mean ± SD) 141 ± 43 141 ± 42 0,78 
LDL (mg/dL) (mean ± SD) 92 ± 35 93 ± 34 0,45 
HDL (mg/dL) (mean ± SD) 34 ± 15 35 ± 14 0,79 
Triglyceride (mg/dL) (mean ± SD) 111 ± 54 110 ± 53 0,96 
Fasting blood glucose (g/dL) (mean ± SD) 102 ± 28 101 ± 27 0,78 
HbA1c (%)(mean ± SD) 5,9 ± 1,9 6 ± 2,1 0,56 
Lactic acid (mmol/L) (mean ± SD) 2,4 ± 1,1 2,1 ± 1,2 0,03 
NT-proBNP at admission (pg/mL) (mean ± 
SD) 
6732 ± 912 3845 ± 426 <0,001 
Potassium (mmol/L) (mean ± SD) 4 ± 1,1 4 ± 0,9 0,34 
Sodium (mmol/L) (mean ± SD) 119 ± 3 125 ± 3 0,01 
pH (mean ± SD) 7,3 ± 0,3 7,32 ± 0,4 0,56 
pCO2 (mmHg) (mean ± SD) 75 ± 23 76 ± 24 0,44 
HCO3 (mmol/L) (mean ± SD) 19 ± 5,1 19 ± 5,0 0,82 
Base excess (mmol/L) (mean ± SD) -7 ± 5 -7 ± 6 0,94 
 
LVEF (%)(mean ± SD) 33,6 ± 6,4 36,4 ± 6,7 0,005 
TAPSE (cm) (mean ± SD) 1,6 ± 0,6 1,6 ± 0,8 0,38 
IVC (cm) (mean ± SD) 2,1 ± 0,6 2,1 ± 0,5 0,36 
PCWP (mmHg) (mean ± SD) 22,2 ± 4,2 21,6 ± 4,3 0,45 
3. Results
3.1. Baseline characteristic
 The baseline characteristics of the study population stratified 
by SACS are presented in Table 2. There were no significant differences 
in demographic characteristics and comorbidities between SACS ≥6 
group and SACS <6 group. Patients with SACS ≥6 were predominantly 
males; more often presented with PND, orthopnea, palpitation, SBP < 
90mmHg, HR >100 bpm, cold and clammy acrals, rales, and Forrester 
wet cold classification (all p-value > 0.05). Additionally, they had a 
worse renal function, more severe lactic acidosis, higher admission 
NT-proBNP, lower value of sodium, and lower LVEF compared to the 
patients with SACS <6 on admission. Regarding medical therapy 
during the index hospitalization, both groups revealed no significant 
difference (all p-value > 0.05). Length of hospital stay among both 
groups was noted to be significantly not different (p=0.36). All patients 
were discharged with no clinical congestion. All patients obtained 
standard heart failure therapy (ACE inhibitor / ARB, β-blocker, and/or 
mineralocorticoid receptor antagonist). The medical therapy regimen 
among both groups at the time of discharge was not significantly 
different. The adherence and compliance of routine drug consumption 
after index hospitalization were measured using Morisky Medication 
Adherence Scale-8 (MMAS-8) whenever patients or their families were 
contacted. During 90-days follow up after discharge, 89 patients 
revealed a score >6 which was considered as good adherence.
3.2. Performance of the SACS as Predictor of Short-term Clinical Outcome
 During 90-days follow-up after discharge, among 89 patients 
with adequate adherence to standard medical treatment, the clinical 
outcome measures were observed in 15 patients (16,8%) for all-cause 
mortality and 20 patients (22.5%) for HF-related rehospitalization, 
respectively (as shown in Table 3). Fig. 1 and Fig. 2 revealed the 
Kaplan-Meier survival curves for both clinical outcomes stratified by 
each SACS. The curves are separated and trends consistent. The 
log-rank test for both outcomes produced a p-value of <0.001, indicat-
ing statistically significant differences in survival curves for both 
outcomes. Similarly, patients with SACS ≥6 had a significantly worse 
prognosis compared to those with SACS < 6 in both clinical outcomes 
measured (p =0.000 and p=0.000, respectively). 
Laboratory Parameter
Echocardiography Parameter
Figure 1. Kaplan-Meier survival analysis demonstrated higher cumula-
tive 90-days all-cause mortality in SACS ≥ 6 (green line) compared to 
SACS < 6 (blue line) (HR 95% CI 9.08; log-rank p value = 0.000)
SACS < 6
SACS ≥ 6
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 Performance of SACS ≥6 among 38 patients with poor 
adherence to standard medical treatment during 90-days follow up was 
found to be less sensitive for prediction of all-cause mortality (sensitivi-
ty 66.7% and specificity 81.2%; AUC 0.740 [95%CI 0.50 – 0.98]; 
p=0.046) and HF-related rehospitalization (sensitivity 70% and 
specificity 85.7%; AUC 0.779 [95%CI 0.59 – 0.96]; p=0.010) as 
compared to SACS <6 (as shown in Fig. 5).
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Figure 2. Kaplan-Meier survival analysis revealed higher cumulative for 
90-days HF-rehospitalization free rate in SACS < 6 (blue line) 
compared to SACS ≥ 6 (green line) (HR 95% CI 11.5; log-rank p value 
= 0.000)
3.3. Performance of the SACS in Comparison to NT-proBNP as Predictor of 
Short-term Clinical Outcome
 We also elucidated the predictive value of SACS ≥6 as 
compared to NT-proBNP ≥5000 pg/mL, in which cut-off of both 
variables were determined during prior derivation study. Goodness of 
fit study using ROC curve were performed. Discriminative ability was 
noted to be fair for NT-proBNP ≥5000 pg/mL (sensitivity 71.4% and 
specificity 80.2%; AUC 0.758 [95% 0.612 – 0.905]; p=0.002) and also 
for SACS ≥6 (sensitivity 71.4% and specificity 77.9%; AUC 0.747 [95% 
0.60 – 0.893]; p=0.003) for prediction of 90-days all-cause mortality 
(as shown in Fig. 3). Addition of NT-proBNP ≥5000 pg/mL to SACS ≥
6 was found to increase discriminative ability of the score to predict 
90-days all-cause mortality (sensitivity 85.7% and specificity 81.4%; 
AUC 0.836 [95% 0.719 – 0.952]; p=0.000). The Hosmer-Lemeshow 
test revealed a good calibration (observed versus predicted outcomes) 
regarding NT-proBNP ≥5000 pg/mL and SACS ≥6 for 90-days 
all-cause mortality (p=0.86 and p=0.75, respectively). 
 Discriminative ability was found to be good for NT-proBNP ≥
5000 pg/mL (sensitivity 80% and specificity 83.8%; AUC 0.819 [95% 
0.707 – 0.931]; p=0.000) and was fair for SACS ≥6 (sensitivity 75% 
and specificity 82.5%; AUC 0.788 [95% 0.667 – 0.908]; p=0.000) for 
prediction of 90-days HF-related rehospitalization (as shown in Fig. 4). 
Addition of NT-proBNP ≥5000 pg/mL to SACS ≥6 was found to 
increase discriminative ability of the score to predict 90-days HF-related 
rehospitalization (sensitivity 90% and specificity 90%; AUC 0.90 [95% 
0.815 – 0.985]; p=0.000). The Hosmer-Lemeshow test also revealed a 
good calibration (observed versus predicted outcomes) regarding 
NT-proBNP ≥5000 pg/mL and SACS ≥6 for 90-days HF-related 
rehospitalization (p=0.86 and p=0.82, respectively). 
Figure 3. Comparison of performance and discriminative ability by 
using ROC curve among NT-proBNP ≥5000 pg/mL at admission 
(yellow line), SACS ≥6 at admission (green line), and both combina-
tion (blue line) for prediction of 90-days all-cause mortality
Figure 4. Comparison of performance and discriminative ability by 
using ROC curve among NT-proBNP ≥5000 pg/mL at admission 
(yellow line), SACS ≥6 at admission (green line), and both combina-
tion (blue line) for prediction of 90-days HF-related rehospitalization
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90-days all-cause mortality (n,%)
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 Post discharge mortality (n,%)
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Table 3. Distribution of clinical outcomes during 90-days follow up 
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4. Discussion
 In our study, the 90-days ACM rate was 16.8%. It was nearly 
similar to the previous meta-analysis study which revealed a 90-days 
ACM in AHF patients of 14.7%.9 The 90-days HFR rate was 22.5% in 
our study, which was similar to a previous meta-analysis study which 
showed a 90-days rehospitalization rate in AHF patients of 22.9%.10 
Our study included patients with LVEF ≤40% and excluded patients 
with isolated RV failure. Right HF secondary to LV dysfunction was 
included and found in 8.9% of the total study population.
 SACS comprises 7 variables (5 clinical variables and 2 labora-
tory variables) which are easily obtained in our daily clinical practice, at 
affordable cost and measured at the time of hospital admission. In our 
study, AHF-rEF patients who admitted with SACS ≥6 revealed a 48% 
increased risk of ACM and 63% increased risk of HFR compared to 
SACS <6 during 90-days follow-up.
 In the HF-rEF subset, congestion is one of the conditions 
which easily found. The higher the grade of congestion, the worse the 
clinical and laboratory presentation may we obtain. Multivariate 
logistic regression analysis of the previous derivation study demonstrat-
ed a number of independent predictors of the short-term outcome, 
which further establish a novel clinical predictive model, known as 
SACS. Orthopnea and PND were found to be an independent predictor 
of both short-term clinical outcome. A previous study revealed that 
persistent orthopnea has been associated with a higher rate of rehospi-
talization and mortality during 6-months follow up.11 Supine position 
results in the shifting of fluid from dependent venous reservoirs around 
the splanchnic area and in the lower extremities, increasing venous 
return (about 250 to 500 mL of fluid) to the thoracic compartment. 
Whereas, PND results as decreased response of respiratory center in the 
brain and blunted adrenergic activity in myocardium during sleep.4 
Rales indicate fluid overload and in the lower extremities, increasing 
venous return (about 250 to 500 mL of fluid) to the thoracic compart-
ment. Whereas, PND results in a decreased response of the respiratory 
center in the brain and blunted adrenergic activity in the myocardium 
during sleep.4 Rales indicate fluid overload and was found to be associ-
ated with poor outcome, if not immediately treated. Presentation of 
cardiogenic shock at admission was associated with poor outcome in 
AHF-rEF, similar to the result of OPTIMIZE-HF.11  
 Hyponatremia in AHF reflected an excessive activation of the 
renin-angiotensin-aldosterone axis, upregulation of the sympathetic 
nervous system, and exaggerated vasopressin release.12 Post hoc 
analysis of ICON study also reported that hyponatremia at admission 
was corresponded to the increase NT-proBNP level and was discovered 
as an independent predictor of 1-year mortality.6 OPTIMIZE-HF and 
ESCAPE study demonstrated an increased mortality risk in AHF 
patients with hyponatremia at admission during 60-180 days follow 
up.12 A previous study revealed that increased serum creatinine level on 
admission was associated with an increase of 12% risk of ACM during 
90-days follow up.13 Tachycardia on admission during the congestion 
period was associated with poor prognosis as well.4
 In the ICON study, NT-proBNP level >5180 pg/mL at admis-
sion was recognized as an independent predictor for short-term 
outcome in AHF; which is similar with the cut-off point expressed in 
our study [6]. In our study, performance of SACS ≥6 has shown fair 
discriminative ability with sensitivity 71% and specificity 78% for 
prediction of 90-days ACM, almost similar to the result found in 
standard biomarker NT-proBNP ≥5000 pg/mL (sensitivity 71% and 
specificity 80%). Additive value of NT-proBNP significantly increase 
the discriminative ability of SACS with sensitivity 86% and specificity 
81% for predict 90-days ACM. Performance of SACS ≥6 has shown fair 
discriminative ability with sensitivity 75% and specificity 82% for 
Figure 5. Discriminative ability subanalysis of SACS ≥6 at admission by using ROC curve among patients with poor adherence to standard medical 
treatment during 90-days follow up for prediction of all-cause mortality (Fig. 5A [AUC 0.74; p=0.046]) and HF-related rehospitalization (Fig. 5B 
[AUC 0.779; p=0.01])
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prediction of 90-days HFR, a little lower to the result found in standard 
biomarker NT-proBNP ≥5000 pg/mL (sensitivity 80% and specificity 
84%). Additive value of NT-proBNP significantly increase the discrimi-
native ability of SACS to excellent with sensitivity 90% and specificity 
90% for predict 90-days HFR.
 Our study has several limitations. First, it included a relative-
ly small number of patients thus could not represent the real picture of 
entire population. Second, has relatively short duration of follow up. 
Third, it was single-center based study. Fourth, the subset of study 
population is limited to HF-rEF. Fifth, the precipitating factors of AHF 
contributing to rehospitalization is difficult to control. Sixth, prognostic 
evaluation of SACS and NT-proBNP in this study is only limited to the 
time of admission.  Despite these limitations, our study demonstrated 
certain novelty or strengths. First, the exclusion criteria in our study 
was strictly defined in order to reduce bias / confounders. Second, all 
of study population receive disease modifying pharmacological therapy 
(eg. ACE inhibitors / ARBs and β-blockers) during hospitalization and 
after discharge. Third, our score was particularly designed for AHF 
population with adequate adherence to standard medical treatment.
5.Conclusion
Our study elucidated a validation of SACS in a cohort of hospitalized 
AHF-rEF patients. SACS revealed a good prognostic value when 
compared to NT-proBNP for prediction of ACM and HFR during 
90-days after index hospitalization in AHF-rEF. Additive value of 
NT-proBNP into SACS demonstrated a higher prognostic value for 
prediction of ACM and HFR during 90-days after index hospitalization 
in AHF-rEF, as well. SACS is a simple and very easily calculated risk 
prediction model, thus can be able to use widely as a risk stratification 
tool in patients hospitalized for AHF. 
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